buy cheap antabuse canadian pharmacy no prescription

MRNA VS. CONVENTIONAL VACCINES

Working Together to Empower Women

Reducing Health Disparities in Latino Communities

Pfizer Women’s Resource Group

Universal vs. Single Payer Healthcare

Making sure that medicines are accessible and affordable for patients is a goal we all share. But the dangerous policy outlined in H.R. 3 could threaten the future of groundbreaking cures.

The policy would allow government “negotiations” on the price of medicines for Medicare. Moreover, this misguided policy would repeal a key provision of the Medicare Part D program – the noninterference clause – that protects coverage and access to medicines for seniors and people with disabilities. Taking away this protection threatens patients’ access to medicines and sacrifices future medical advances.

There are major problems with H.R. 3:

  • It puts innovation at risk. The policy could lead to an estimated 59 fewer new treatments over the next three decades. A new study by the Congressional Budget Office found that it would result in fewer groundbreaking treatments for patients in desperate need of relief.
  • It threatens the U.S. advantage. Patients who live in countries with a similar drug pricing policy often experience significant delays in accessing new treatments. We can’t allow a government power grab to put patients’ lives at risk.
  • It overpromises. While the policy claims it will lower healthcare costs for all patients, less than 1% of seniors on Medicare would see reduced out-of-pocket costs. In fact, some experts estimate that the policy may even increase insurance premiums for seniors.

Adopting H.R. 3 could result in serious consequences for patients and the U.S. healthcare system. To lower healthcare costs, you should reject government “negotiation” policies and support real solutions to make medicines more affordable and accessible, such as capping annual out-of-pocket costs in Part D.









Source: Read Full Article